SAB0 Stock Chart & Stats
€11.60
-€0.30(-2.24%)
At close: 4:00 PM EDT
€11.60
-€0.30(-2.24%)
Day’s Range― - ―
52-Week Range€10.90 - €14.10
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.81B
Enterprise Value€10.82K
Total Cash (Recent Filing)€653.73M
Total Debt (Recent Filing)€5.84B
Price to Earnings (P/E)15.8
Beta0.23
Next Earnings
Feb 22, 2027EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding494,237,950
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)1.24
Price to Sales (P/S)0.96
P/FCF Ratio13.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.76
Revenue Forecast (FY)€6.88B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Profit GrowthBroad-based revenue and earnings growth supports Sonic’s ability to expand its diagnostic network and absorb fixed laboratory costs. Sustained top-line momentum can strengthen operating scale and provide funding for technology, capacity and strategic growth.
Advanced Diagnostics And Organic DemandUnderlying volume growth and rising specialist engagement indicate durable demand for clinically important testing. Advanced diagnostics also offers a higher-value growth avenue, supporting customer relevance, service differentiation and potential mix improvement over time.
M&A Integration And Operational SavingsSonic is demonstrating an ability to integrate acquisitions and extract efficiencies across its international platform. Synergy capture, procurement savings and U.S. restructuring can improve scalability and create a repeatable foundation for future expansion.
Bears Say
Margin Compression And Weaker Cash ConversionCurrent profitability remains below earlier peak levels, limiting the earnings benefit from revenue growth. Weaker conversion of accounting profit into free cash flow reduces flexibility for acquisitions, dividends and investment, and makes performance less predictable.
Regulatory And Contract-related Earnings PressureReimbursement changes can permanently lower revenue per service, while delayed U.K. integration postpones expected efficiencies. These pressures may require productivity measures or synergies merely to protect margins, constraining medium-term earnings growth.
Higher Leverage And Capital IntensityRising debt dependence and higher financing costs reduce financial flexibility, particularly while major property and transformation investments continue. Elevated capital intensity can delay cash returns and increase sensitivity to operational or reimbursement setbacks.
Sonic Healthcare News
SAB0 FAQ
What was Sonic Healthcare Limited’s price range in the past 12 months?
Sonic Healthcare Limited lowest stock price was €10.90 and its highest was €14.10 in the past 12 months.
What is Sonic Healthcare Limited’s market cap?
Sonic Healthcare Limited’s market cap is €5.81B.
When is Sonic Healthcare Limited’s upcoming earnings report date?
Sonic Healthcare Limited’s upcoming earnings report date is Feb 22, 2027 which is in 159 days.
How were Sonic Healthcare Limited’s earnings last quarter?
Sonic Healthcare Limited released its earnings results on Aug 19, 2026. The company reported €0.441 earnings per share for the quarter, beating the consensus estimate of €0.397 by €0.044.
Is Sonic Healthcare Limited overvalued?
According to Wall Street analysts Sonic Healthcare Limited’s price is currently Overvalued.
Does Sonic Healthcare Limited pay dividends?
Sonic Healthcare Limited does not currently pay dividends.
What is Sonic Healthcare Limited’s EPS estimate?
Sonic Healthcare Limited’s EPS estimate is 0.33.
How many shares outstanding does Sonic Healthcare Limited have?
Sonic Healthcare Limited has 494,237,950 shares outstanding.
What happened to Sonic Healthcare Limited’s price movement after its last earnings report?
Sonic Healthcare Limited reported an EPS of €0.441 in its last earnings report, beating expectations of €0.397. Following the earnings report the stock price went down -9.996%.
Which hedge fund is a major shareholder of Sonic Healthcare Limited?
Currently, no hedge funds are holding shares in DE:SAB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sonic Healthcare Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.45%
12-Months-Change
Fundamentals
Return on Equity
5.54%
Trailing 12-Months
Asset Growth
6.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sonic Healthcare Limited
Headquartered in Sydney, Australia, Sonic Healthcare Limited, established in 1934, is a global provider of medical diagnostic and healthcare services. The company delivers a comprehensive range of laboratory medicine (pathology) services, alongside extensive diagnostic imaging and radiology capabilities, which include MRI, CT scans, ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Beyond diagnostics, Sonic Healthcare also offers various primary care medical solutions. These encompass general practitioner services, occupational health support, remote healthcare provisions, community and in-home nursing, primary care research initiatives, health assessment technologies, clinical trial management, and chronic disease management programs. These crucial services are extended to medical professionals, hospitals, community health organizations, and their respective patients. Furthermore, the company provides administrative support and facilities to medical practitioners. Sonic Healthcare maintains a significant international presence, operating across Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland, Belgium, and Ireland.
SAB0 Company Deck
SAB0 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance picture: strong revenue, EBITDA and NPAT growth, solid organic expansion, and notable success in advanced diagnostics and M&A integration (notably Germany and Switzerland). Management also outlined proactive investments in digital transformation and clear U.S. turnaround actions expected to deliver AUD 25–30 million in FY2027 earnings. However, several near-term headwinds were emphasized, including regulatory fee cuts in Switzerland (CHF 20m), U.K. contract integration delays, software impairments and legacy IT write-downs, higher interest and capex in FY2026, FX and policy uncertainties (PAMA, GOÄ). On balance the highlights (growth, synergy capture, digital investment and disciplined capital management) outweigh the lowlights, although they limit near-term upside and keep guidance conservative.View all DE:SAB0 earnings summaries